About InVivoMAb anti-human CD220 (Insulin Receptor)
The IR 83-22 monoclonal antibody reacts with human CD220, also known as insulin receptor. CD220 is a type I transmembrane receptor tyrosine kinase which, upon binding to insulin, initiates several cellular effects, including glucose uptake, cell growth, differentiation, and apoptosis. These effects primarily occur in skeletal muscle, fat, and the liver. Neuronal CD220 signaling has been shown to have an important role in energy homeostasis, reproduction, and the development of neurodegenerative diseases. The IR 83-22 antibody has been shown to inhibit approximately 80% of insulin binding to IM-9 insulin receptor expressing cells.
InVivoMAb anti-human CD220 (Insulin Receptor) Specifications
|Recommended Isotype Control(s)|
|Recommended Dilution Buffer|
|Immunogen||Human IM-9 lymphocytes|
|Sterility||0.2 μM filtered|
|Production||Purified from tissue culture supernatant in an animal free facility|
|Molecular Weight||150 kDa|
|Storage||The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.|
InVivoMAb anti-human CD220 (Insulin Receptor)
Soos, M. A., et al. (1986). “Monoclonal antibodies reacting with multiple epitopes on the human insulin receptor.” Biochem J 235(1): 199-208. PubMed
Monoclonal antibodies for the human insulin receptor were produced following immunization of mice with IM-9 lymphocytes and/or purified placental receptor. Four separate fusions yielded 28 antibodies, all of which reacted with receptor from human placenta, liver and IM-9 cells. Some antibodies cross-reacted to varying degrees with receptor from rabbit, cow, pig and sheep, but none reacted with rat receptor. At least 10 distinct epitopes were recognized as indicated by species specificity and binding competition experiments. All of these epitopes appeared to be on extracellular domains of the receptor as shown by binding of antibodies to intact cells. In some cases the epitopes were further localized to alpha or beta subunits by immunoblotting. Several antibodies inhibited binding of 125I-insulin to the receptor, some had no effect on binding, and others enhanced the binding of 125I-insulin. It is concluded that these antibodies will be valuable probes of receptor structure and function.